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Abstract 
Background: Statistical analysis plans increase the transparency of decisions made in the 
analysis of clinical trial results. The purpose of this paper is to detail the planned analyses for 
the PREVENT trial, a randomized, placebo-controlled trial of patient education for acute low 
back pain. Results: We report the pre-specified principles, methods, and procedures to be 
adhered to in the main analysis of the PREVENT trial data. The primary outcome analysis 
will be based on Mixed Models for Repeated Measures (MMRM), which can test treatment 
effects at specific time points, and the assumptions of this analysis are outlined. We also 
outline the treatment of secondary outcomes and planned sensitivity analyses. We provide 
decisions regarding the treatment of missing data, handling of descriptive and process 
measure data, and blinded review procedures. Conclusions: Making public the pre-specified 
statistical analysis plan for the PREVENT trial minimizes the potential for bias in the 
analysis of trial data, and in the interpretation and reporting of trial results. Trial registration: 
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612001180808  
 
Bullet Points  
 Patient Education is recommended in the primary care management of acute low back 
pain.  The PREVENT Trial is the first placebo-controlled randomized trial to evaluate 
the efficacy of Patient Education. 
 Statistical analysis plans increase the transparency around how researchers plan to 
estimate and interpret treatment effects from randomized trials. 
 This protocol describes the pre-specified principles, methods, and procedures to be 
adhered to in the statistical analysis of the PREVENT trial data. 
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Background 
The PREVENT Trial is a randomised, placebo-controlled trial of patient education for acute 
low back pain. The purpose of this Statistical Analysis Plan is to outline planned statistical 
analysis methods for the primary and secondary outcomes of the trial.  
 
Trial overview 
The trial is a two-arm placebo-controlled trial. Patients were randomized to receive two, 1-hr 
sessions of Patient Education based on Explain Pain
1
 or two, 1-hr sessions of Sham 
Education based on a reflective, non-directive approach,
2
 in addition to guideline-based care 
for acute low back pain (NHMRC APP1047827). The study was prospectively registered 
(ACTRN=12612001180808) and the study protocol has been published.
3
 Patients were 
followed up at 3, 6, and 12 months post-randomization.  
 
Trial objectives 
Primary Objective 
1. Determine whether Patient Education in addition to clinical guideline-based care for 
acute low back pain reduces the intensity of low back pain at 3 months compared to 
Sham Education in addition to clinical guideline-based care. 
 
Secondary Objectives 
1. Determine whether any effect of Patient Education on the intensity of low back pain 
at 3 months compared the Sham Education can be maintained at 6 and 12 months. 
2. Determine whether Patient Education increases the proportion of patients who 
recover from low back pain (i.e. who do not develop chronic low back pain) by 3 
months compared to Sham Education. 
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3. Determine whether Patient Education can reduce disability, depression, or pain 
attitudes, or healthcare use at 3, 6 and 12 months, compared to Sham Education. 
 
Statistical Analysis  
General principles 
Two researchers blind to group allocation will perform the analysis independently. That is, 
the researcher will know which participants share a group, but not which group that is. All 
results will be cross-checked for errors. In cases where participants did not receive the 
treatment as allocated, treatment evaluation will be based on the principle of intention-to-
treat. In other words, the analysis will only include observed responses from participants in 
the trial arm they were allocated to, regardless of whether they complied with the treatment 
and even if the last observed response was baseline. We will calculate and interpret between 
group differences and 95% confidence intervals for all outcomes. Statistical tests will be two-
tailed with alpha set at p=<0.05. 
 
Process measures 
Adherence 
We recorded attendance for all participants at both trial sessions using a study calendar. We 
will use these data to assess whether the proportion of participants who successfully 
completed both trial sessions was different between trial arms. If >5% of participants do not 
complete both trial sessions, we will compute a “Complier Average Causal Effect.”4 
 
Treatment fidelity 
We assessed treatment fidelity by audio recording the trial sessions. Two researchers, experts 
in Patient Education (LM) and Sham Education (MN) who are blinded to group allocation, 
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will evaluate a random 10% sample of the trial session recordings to determine whether the 
participant was receiving Patient Education or Sham Education. Kappa will be used to 
determine agreement. 
 
Credibility 
We assessed credibility using the Credibility and Expectancy Questionnaire
5
 immediately 
after the trial physiotherapist provided the treatment rationale. We will compare the between 
group mean scores of the Credibility and Expectancy Questionnaire using t test to evaluate 
whether treatment credibility was different in each trial arm. 
 
Blind review of data integrity and handling 
All data were collected using online forms. Because the online data collection system 
required only minimal handling, data will be checked but not double entered as we originally 
planned and as stated in our protocol.
3
 To ensure data integrity, a blind assessor will check 
each variable for out of range or implausible values. Once all data have been checked, we 
will import the dataset in panel format, into Stata V13.
6
 
 
Participant recruitment and retention 
A flow chart describing the numbers of individuals at each stage of the trial from 
eligibility to final assessment will be reported, according to the CONSORT statements
7
 
(see Figure 1).  
 
Baseline description 
We will examine the distribution of all baseline variables stratified by treatment group. 
Continuous variables will be summarised using the following statistics: number (non-missing 
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sample size), mean and standard deviation for approximately normally distributed variables; 
median, minimum, maximum and interquartile range for non-normally distributed variables.  
Normality will be evaluated using frequency histogram and skewness statistics. The number 
of missing observations will also be reported. Categorical variables will be summarized by 
percentages along with their frequencies (numerator) and the number of patients for whom 
data are available (denominator). Difference between arms will not be tested statistically, but 
any important imbalance, based on the judgment of the research team, will be mentioned and 
will be marked with an asterisk (*). 
 
Primary analysis  
We calculated that a sample size of 202 participants would provide an 80% power of 
detecting a mean difference between trial arms of one-point on a 10-point pain intensity scale 
assuming a standard deviation of 2.3, an α of .05, and allowing 15% loss to follow-up.3 To 
determine the effect of Patient Education on pain intensity we will use longitudinal mixed 
models.
8
 In longitudinal studies such as randomized trials, mixed models can produce 
unbiased estimates of treatment effects. A mixed model contains both fixed and random 
effects. In this analysis, the intervention will be modelled as a fixed effect and, to account for 
the dependence of repeated measures, the intercepts will be modelled as random effect 
(Equation 1). We will use an unstructured correlation matrix to specify the model. Our 
expectation is that the outcome of pain intensity will be normally distributed. Time will be 
treated as a dummy-coded categorical variable and we will examine group x time interactions 
to determine treatment effects. Conclusions about the effectiveness of Patient Education will 
be based on the group x time interaction effect and its 95% confidence interval at 3 months.  
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Equation 1 - Mixed Model for Repeated Measures (MMRM) regression equation for the 
primary analysis (based on Ashbeck and Bell
9
): 
 
Yij = β1 t1 + β2 t2 + β3 t3 + β4 t4 + β5 treati x t1 + β6 treati x t2 + β7 treati x t3 + β8 treati x t4 + βi + eij 
 
Yij = the outcome for the i
th
 participant at the j
th
 time 
i = 1,…,n = 202 
j = 1, 2, 3, 4, 
t1 = indicator variable for time 1 (baseline), t2 for time 2 (3 months), t3 for time 3 (6 months), t4 for time 4 
(12 months) 
treati = 0 (control), treati =1 (treatment). The effects of the treatment and the treatment-time interaction are 
modelled as fixed effects. 
βi = ~ N(0, b
2
) between-person effects, with b
2
 between-person variance. The between-person effects are 
modelled as random effects. 
eij = ~ N(0, e
2
) within-person effects, with e
2
 within-person variance 
 
 
Assumptions of the Mixed Model for Repeated Measures (MMRM) analysis 
The mixed model analysis requires assumptions about the data. These include independence 
of observations, normality and heteroscedasticity. Missing data are assumed to be Missing at 
Random. Missing at Random describes the probability of a missing observation being 
independent of prior observations but conditional on other observed values. MMRM analyses 
also assume a correlation structure between the repeated measurements. The correlations can 
be fixed (structured model), decaying (autoregressive model) or unconstrained (unstructured 
model). We have assumed unconstrained correlations between the repeated assessments.  
 
Secondary analysis  
Traeger 
PREVENT Trial Analysis Plan 
Persistence of effects on pain and disability 
To evaluate the effects of Patient Education on pain intensity at 6 and 12 months, we will 
examine the relevant group x time interactions from the longitudinal mixed model used for 
the primary analysis. We will build a separate model to examine intervention effects on 
disability at 3, 6 and 12 months. We will specify the disability model in the same way as in 
the primary analysis (Equation 1), exchanging the Y outcome variable to disability measured 
on a continuous scale (Roland Morris Disability Questionnaire).
10
  
 
Development of chronic low back pain 
To assess the number of participants who transition from acute low back pain to chronic low 
back pain we will categorize participants according to our definition of chronic low back 
pain: ≥2/10 pain intensity and no periods of recovery at 3 month follow-up.3 To evaluate the 
effects of Patient Education on the development of chronic low back pain, we will estimate 
the ratio of the odds of having chronic low back pain using a Generalized Mixed Effects 
Model with a logit link and a random intercept.  The model will provide odds ratio between 
the two arms of experiencing a transition from acute to chronic low back pain. 
 
 
Short- and long-term effects on pain, disability, depression, pain attitudes and healthcare use 
We will undertake exploratory analyses on all secondary outcomes. To test intervention 
effects on continuous secondary outcomes (disability, depression, pain, global change, pain 
attitudes and healthcare visits) we will examine group x time interactions from the 
longitudinal mixed models at each follow-up time point.  
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Four secondary outcomes were categorical variables: healthcare use (passive modalities e.g. 
medication, manual therapy vs active modalities e.g. exercise, rehabilitation); choice of 
practitioner; recurrence; further investigations required. For the outcomes with two categories 
we will use logistic regression models to determine between group differences. For the 
outcome with four categories (choice of practitioner), we will use a multinomial logistic 
regression.  
 
Sensitivity analysis 
Out-of-trial therapy 
We will evaluate the effect of out-of-trial therapy (number of healthcare visits) as a post-
randomization confounder. The purpose of this sensitivity analysis is to assess the influence 
of Sham Education, which may have unintentionally led participants to seek out-of-trial 
therapy. We will conduct a mediation analysis to estimate the natural direct effect
11
 of Patient 
Education on pain intensity at 3 months that eliminates the indirect effect of Sham Education 
on pain intensity through out-of-trial therapy. 
 
Reporting data 
Continuous outcomes (e.g. low back pain intensity scale) will be summarised by number of 
data available, mean and standard deviation at each data collection point (Baseline, 3, 6 and 
12 months). We will display the treatment effect, estimated as the mean pain intensity scale 
difference at each time point, along with the corresponding 95% confidence interval and the 
level of significance. Categorical variables will appear as frequencies and percentages at each 
time point. We will report overall odds ratios (95 % confidence interval) and the level of 
significance. 
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Figure 1. CONSORT 2010 Flow Diagram for planned reporting of the PREVENT Trial 
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